MicrRNA-based mesothelioma test available from Rosetta Genomics

Jan 6, 2009

Rosetta Genomics has announced that its microRNA-based test to diagnose mesothelioma is now commercially available to physicians. This molecularly based test is intended to help doctors in distinguishing between lung cancer and mesothelioma. The test is called miRview™ meso and is Rosetta Genomics’ third molecular diagnostic test to go on the market. It is available through Rosetta Genomics’ laboratory in Philadelphia, Pennsylvania.

Mesothelioma is almost exclusively caused by asbestos exposure, and lung cancer is also associated with asbestos exposure. Distinguishing pleural mesothelioma and lung cancer can be challenging to physicians and pathologists in some cases. A test that assists in this determination is a boon for physicians and patients alike because the correct diagnosis is critical to selecting the best course of treatment.

For the full story, go to Reuters.

Latest News Stories